Skip to main content

Depression, Postpartum

Neurology
2
Pipeline Programs
7
Companies
10
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Neurology is a $26.9B market dominated by a single blockbuster anticoagulant (ELIQUIS), representing a mature but consolidating therapeutic area.

$26.9B marketMature→ Stable30 products15 companies

Key Trends

  • Extreme market concentration: 68% of spending driven by one FXa inhibitor product
  • Psychiatric and migraine therapies emerging as secondary growth drivers
  • High clinical trial activity (8,279 trials) signals continued pipeline development

Career Verdict

Neurology offers solid career stability with good hiring demand, but limited upside growth—best suited for professionals seeking established market positions rather than emerging-area innovation.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#1ELIQUISStable
$18.3B
Bristol Myers Squibb·Launch15.0yr
$1.8B
#3BRILINTAStable
$692M
AstraZeneca·Peak10.2yr
#4NUPLAZIDStable
$596M
$530M
Johnson & Johnson·Peak15.6yr

Drug Class Breakdown

FXa Inhibitors (anticoagulant)
$18.3B(68%)

market-defining single product

Dopamine/Serotonin Antagonists (psychiatric)
$2.4B(9%)

stable mature class

P2Y12 Receptor Antagonists (antiplatelet)
$692M(3%)

niche but stable

5-HT2A Inverse Agonists (psychiatric)
$596M(2%)

specialty indication focus

CGRP Receptor Antagonists (migraine)
$931M(3%)

emerging growth segment

Immunomodulators (MS)
$747M(3%)

stable with LOE risk

Other mechanisms
$2.6B(10%)

diverse small products

Career Outlook

Stable

Neurology represents a mature, cash-generative market with limited growth tailwinds but strong hiring stability. The dominance of ELIQUIS creates a bifurcated career landscape: high-opportunity positions in emerging segments (CGRP antagonists, psychiatric therapeutics) and commoditized roles in anticoagulant franchises. Job availability is solid but growth expectations should be tempered relative to oncology or immunology.

Breaking In

Entry-level professionals should target clinical operations or commercial support roles at J&J, AstraZeneca, or Sanofi to build domain expertise in neurology disease states and competitive dynamics.

For Experienced Professionals

Experienced professionals should prioritize emerging mechanism roles (CGRP, tau-targeting programs) or pivot to medtech/neurotech (Stryker, Medtronic) to capture higher growth and salary potential than traditional pharma incumbents.

In-Demand Skills

Medical Science Liaisons (MSL) for specialist engagementClinical trial operations expertisePsychiatric/neurodegenerative disease educationRegulatory affairs (given patent cliff activity)Commercial strategy around branded/generic transitions

Best For

Medical Science LiaisonCommercial Brand Manager (anticoagulant/psychiatric franchises)Clinical Operations ManagerRegulatory Affairs SpecialistClinical Development Manager (CGRP/immunomodulator pipelines)

Hiring Landscape

$100K-$199K

Neurology shows moderate but distributed hiring across pharma and medtech employers, with 4,186 total jobs listed. Commercial functions lead (947 roles, $169K avg), followed by clinical operations (467 roles, $132K avg), indicating bias toward commercialization over R&D. Takeda leads external hiring (762 jobs) with strong representation in contract research and CRO spaces.

4,186
Open Roles
5
Companies Hiring
5
Departments

Top Hiring Companies

762Growing
434Stable
302Stable

By Department

Commercial(23%)
$169K
Clinical Operations(11%)
$132K
Engineering(8%)
$199K
IT(4%)
$100K
Manufacturing(3%)
$170K

Commercial and clinical operations roles dominate, offering stable mid-career positions; engineering roles command premium salaries ($199K), suggesting strong device/neurotech hiring pockets.

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Human BioSciences
Human BioSciencesWV - Martinsburg
2 programs
2
Intranasal OxytocinPhase 21 trial
OxytocinPhase 21 trial
Active Trials
NCT03593473Completed109Est. Jul 2023
NCT02505984Completed56Est. May 2023
GSK
GSKLONDON, United Kingdom
2 programs
Pravastatin aloneN/A1 trial
Tricyclic ADN/A1 trial
Active Trials
NCT01602913Completed1Est. May 2012
NCT01587729Completed1Est. Jul 2014
ViiV Healthcare
ViiV HealthcareNC - Durham
2 programs
Pravastatin aloneN/A
Tricyclic ADN/A
Biogen
BiogenCAMBRIDGE, MA
2 programs
ZuranoloneN/A2 trials
SAGE-217PHASE_31 trial
Active Trials
NCT07047820Recruiting200Est. Aug 2026
NCT05655507Completed19Est. Oct 2024
NCT04442503Completed200Est. Apr 2022
March Biosciences
March BiosciencesTX - Houston
1 program
Healing @ Home ProgramN/A1 trial
Active Trials
NCT06877104Recruiting156Est. Nov 2026
Neuronetics
NeuroneticsMALVERN, PA
1 program
NeuroStar Transcranial Magnetic StimulationN/A1 trial
Active Trials
NCT01842542Terminated25Est. Aug 2015
Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
1 program
Perinatal Emotion and Relationships Longitudinal StudyN/A1 trial
Active Trials
NCT03027037Completed150Est. Jan 2018

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
BiogenSAGE-217
Human BioSciencesIntranasal Oxytocin
Human BioSciencesOxytocin
BiogenZuranolone
BiogenZuranolone
March BiosciencesHealing @ Home Program
Colorado TherapeuticsPerinatal Emotion and Relationships Longitudinal Study
NeuroneticsNeuroStar Transcranial Magnetic Stimulation
GSKPravastatin alone
GSKTricyclic AD

Clinical Trials (10)

Total enrollment: 917 patients across 10 trials

A Study to Evaluate the Efficacy and Safety of SAGE-217 in Participants With Severe Postpartum Depression (PPD)

Start: Jun 2020Est. completion: Apr 2022200 patients
Phase 3Completed
NCT03593473Human BioSciencesIntranasal Oxytocin

Inhaled Oxytocin and HPA Axis Reactivity

Start: Feb 2019Est. completion: Jul 2023109 patients
Phase 2Completed

Preventing Postpartum Depression With Intranasal Oxytocin

Start: Jan 2016Est. completion: May 202356 patients
Phase 2Completed

Zuranolone Pharmacokinetics (PK) and Safety Study Adolescent Participants With Major Depressive Disorder (MDD)

Start: Apr 2023Est. completion: Oct 202419 patients
Phase 1Completed

A Study to Learn More About How Zuranolone Affects Postpartum Depression Symptoms in Participants Who Took it Within 1 Year After The End of Their Pregnancy

Start: Jun 2025Est. completion: Aug 2026200 patients
N/ARecruiting
NCT06877104March BiosciencesHealing @ Home Program

Healing at Home 2.0 - Enhanced Chat Tool for Lowering Postpartum Depression

Start: Mar 2025Est. completion: Nov 2026156 patients
N/ARecruiting
NCT03027037Colorado TherapeuticsPerinatal Emotion and Relationships Longitudinal Study

Perinatal Emotion and Relationships Longitudinal Study

Start: Nov 2015Est. completion: Jan 2018150 patients
N/ACompleted
NCT01842542NeuroneticsNeuroStar Transcranial Magnetic Stimulation

Efficacy and Safety Study of NeuroStar TMS Therapy in Patients With Major Depressive Disorder With Postpartum Onset

Start: Dec 2013Est. completion: Aug 201525 patients
N/ATerminated
NCT01602913GSKPravastatin alone

Type II Diabetes Mellitus in Patients Exposed to Pravastatin and Paroxetine

Start: Dec 2011Est. completion: May 20121 patients
N/ACompleted
NCT01587729GSKTricyclic AD

IMI PROTECT(WP2): Antidepressants & Fractures

Start: Nov 2011Est. completion: Jul 20141 patients
N/ACompleted

Related Jobs in Neurology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 actively recruiting trials targeting 917 patients
7 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.